Insulin is the treatment people most want to reduce: it requires more frequent dosing, it causes hypoglycemia, and it drives weight gain. Whether escalating a GLP-1 drug lets people take less of it is a practical question, and a chart review at a Veterans Affairs center followed 62 patients through the dose steps to find out [1]. The related question of swapping mealtime doses entirely is covered on this site’s sister publication.
The pattern is stepwise. Total daily insulin fell 5.6% by the time the 1 mg dose started, and 22.2% by the 2 mg step, and 36.9% after at least three months at 2 mg. HbA1c went from 7.7% to 7.1% across the same period, which is the combination that matters: less insulin and better control, not one traded for the other. What the same drugs do to weight across that stretch is pooled in the weight-loss averages.
A monotonic relationship across three dose steps is more persuasive than a single before-and-after comparison would be, because a confounder would have to track the escalation schedule to produce it. That is the strongest thing about this study, and it is working against real limitations: 62 patients at one center, retrospective, with no control group and no way to separate the drug from everything else that changes over months of active diabetes management.
One detail matters for anyone reading across from the weight literature. Semaglutide 2 mg is a diabetes dose with a diabetes label; the weight-management product is 2.4 mg and is a different prescription. The dose question generally is set out in the network meta-analysis of nineteen drugs, and what happens at the top of the ladder in titration and nausea.
The practical implication is worth stating plainly because it is easy to miss: if insulin requirements fall by a third, insulin doses must be actively reduced as the GLP-1 dose rises, or hypoglycemia follows. That is a prescriber’s job and not a thing to manage alone, which is one more reason the variable clinical support described in the analysis in older adults and the monitoring gaps in vitamins and minerals on a GLP-1 matter more than they appear to.